The researchers have demonstrated that genetic and pharmacological approaches can be used to lower levels of toxic metabolites in the nervous system and thereby alleviate several symptoms of neurodegeneration.
"Our research is focused on better understanding of the mechanisms that contribute to onset and progression of disease symptoms in neurodegenerative disorders," said Professor Flaviano Giorgini, from the University of Leicester in UK.
"These are diseases in which specific populations of nerve cells within the brain die, leading to severe problems in movement and cognitive deficits in patients," Giorgini said.
"Our hope is that by improving our knowledge of how these nerve cells become sick and die in the brain, we can help devise ways to interfere with these processes, and thereby either delay disease onset or prevent disease altogether," Giorgini said.
Also Read
In the past, the researchers have found that they can use genetic approaches to inhibit (or "mute") the activity of two critical enzymes in this pathway - TDO and KMO - which lowers levels of the toxic metabolites and reduces nerve cell loss in a fruit fly model of Huntington's disease.
In the current study they have uncovered how inhibiting these two enzymes improves "symptoms" in flies because of increased levels of a "protective" kynurenine pathway metabolite known as kynurenic acid which counteracts the effects of the toxic metabolites.
"For example, we find that if we inhibit either TDO or KMO in Huntington's flies we reduce loss of neurons. In Alzheimer's or Parkinson's flies we see extension of the shortened lifespan exhibited by these flies, and we also reverse the defects they have in movement," he said.
"We have even used a drug-like chemical to inhibit TDO and found that this also alleviates 'symptoms'," Giorgini added.